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population and economy against potentially troublesome and resource intensive 
outbreaks of infectious diseases.
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tHe ItalIaN NatIoNal HealtH system PersPectIve
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Objectives: A new scenario of therapy for HCV infection is being established 
with the approval. The aim of this study is to evaluate the long-term health out-
comes and the willingness to pay of new anti-HCV treatment from the Italian soci-
etal perspective. MethOds: A multistate model was developed to estimate the 
HCV-infection process in a theoretical cohort. The Markov process considered 
12 health states (F0, F1, F2, F3, Compensated cirrhosis (F4), SVR, decompen-
sated cirrhosis, HCC, Transplantation (1 year), Transplantation (years later), 
HCV-related death and death from other causes) and 42 transition probabilities. 
The model was informed with available data published in national and interna-
tional literature. Effectiveness of new treatment strategies was estimated from 
literature review. Cumulative cases of HCV-related diseases, direct and indirect 
medical costs, avoided by the increased effectiveness of new treatments, were 
estimated. Results: The cohort of subjects with chronic HCV in 2013 amounts 
to 267.190 subjects, of these about 17,600 patients F3-F4 are treated with drug 
therapy. Cumulative cases of HCV-related diseases who succeed in preventing by 
the increased effectiveness of new treatments amounted to 47.433 after 7 years, 
156.507 after 17 years, 256.942 after 27 years. The direct net medical costs, after 
the cost of the drug, amounted to € 18,13, € 72,33 and € 143,24 millions after 7, 17 
and 27 years respectively, and € 166,51, € 950,3 and € 551,53 attributable to indirect 
costs avoided, for the same time horizons. Furthermore, it was estimated that each 
patient treated with new drugs achieves a reduction of expenditure of about € 12,000 
in terms of direct costs, and € 4,000 in terms of indirect costs. cOnclusiOns: In 
conclusion, an important share of the cost per treated patient can be compensated 
by the reduction of direct and indirect costs guaranteed by the effectiveness of new 
treatments.
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vaccINes across euroPe
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Objectives: While the practice of Health Technology Assessment (HTA) has been 
well established there is wide variation in the processes by which public reimburse-
ment decisions for vaccines are made in comparison to medicines and devices. 
The objective of this study was to compare the assessments of vaccines across 
Europe (UK, France, Germany, Italy, Spain), and to critically appraise the systems 
using the key principles for the conduct of HTA (Drummond et al, 2008). MethOds: 
A systematic review of economic modeling of vaccines, supplemented by a tar-
geted review of key stakeholder websites across Europe for previous assessments 
of vaccines was conducted. A search of Medline, Embase, Econlit and NHSEED was 
conducted and abstracts were reviewed by two independent reviewers against pre-
specified criteria for inclusion. Data from relevant articles was extracted and quality 
assessed. Country HTA websites were hand-searched. The evidence was synthesised 
to provide an overview of the strengths and weaknesses of the appraisal processes 
in each of the European countries. Results: The review highlighted the inher-
ent difficulties in health economic modeling using standard HTA processes as the 
long-term impact of vaccines is unknown, leading to wide variation in assumptions 
and methods of extrapolation. The literature identified highlighted the inherent 
uncertainty surrounding the long-term impact of vaccines, which directly impacts 
the cost-effectiveness. The review also highlighted the importance of budget 
impact of vaccines when making a decision. When compared to the key princi-
ples of HTA, all countries failed to meet all of the criteria. cOnclusiOns: The 
economic evaluations identified indicated that the cost-effectiveness of a vaccine 
was heavily dependent on the assumptions surrounding uptake and carriage. The 
review indicated that HTA decisions on vaccines are driven by cost-effectiveness 
and budget impact, which may lead to underestimating the potential clinical and 
public health benefits.
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Objectives: We performed national survey of behavior, attitudes and practice of 
general practitioners (GP) and specialists (pediatricians, ENT, pulmonologists) at 
the field of antimicrobial (ATB) use for respiratory tract infections. MethOds: A 
34-item iPad iOS survey was performed personally with each GP and specialist 
during 7 months period. Results: The survey was completed by 357 GPs and spe-
cialists (61,9% and 38,1%, respectively). GPs and specialists were situated mostly in 
areas with population higher than 5000 people (49,3% and 48,5%), but GPs served 
significantly more often in area with population less than 5000 people compared 
to specialists (P< 0,001, CI 0,13 – 0,60). There was significantly higher number of GPs 
with practice shorter than 5 years compared to specialists (P< 0,01, CI 0,02-0,64). 
GPs used their own clinical experience in prescribing ATB more often compare to 
specialists (61,1% vs 43,4%, P< 0,01, CI 0,31-0,77) and specialist used more often ATB 
susceptibility reports compared to GPs (18,4% vs 8,1%, P< 0,01, CI 1,27-5,10), which 
also corresponds with frequency of checking susceptibility reports on monthly basis 
Objectives: To document the proportion of national healthcare expenditures 
that is devoted to vaccines across Western Europe and its evolution over the past 
years. MethOds: Seven countries were selected: the 5 biggest countries in terms 
of population accounting for ≈317 million inhabitants in 2015 (Germany, England, 
France, Italy, and Spain) and 2 smaller countries from northern and southern 
Europe: Sweden and Portugal. This panel of countries constitutes a good mix of 
vaccine procurement modalities (centralized/decentralized, tender/reimburse-
ment) across Western Europe. Data search was performed on both OECD online 
databases and national official sources for healthcare and vaccine expendi-
tures from 2008 (2006 for England) until the most recent year available (usually 
2012/2013). Results: Healthcare expenditures have increased in all countries 
but Spain. Increases ranged from +3%/year in France to+6%/year in England. In 
the meantime, despite heterogeneous availability, vaccine spending diminished 
markedly in Germany (9%/year from 2008 to 2013), Spain (-7%/year from 2008 
to 2012) and France (-4%/year from 2008 to 2013). Only Sweden (SEK 1.72 Bn in 
2013, +6%/year from 2011 to 2013) and England (£0.40 Bn in 2010/11, +14%/year 
from 2006/07 to 2010/11) have increased their spending on vaccines. The pro-
portion of healthcare expenditures allocated to vaccines ranged from 0.45% in 
Germany (€ 0.82/182.7 Bn in 2013) down to 0.25% in Spain (€ 0.17/ 68.6 Bn in 2012) 
and France (€ 0.63/248 Bn in 2013). When available, OECD data showed similar 
proportions and evolution patterns in most cases. cOnclusiOns: Vaccination 
involves low levels of healthcare investments in Europe (< 0.5%) compared to 
the far-reaching public health benefits it procures. We evidenced a net trend 
towards a decrease over the past years, except for Sweden and England. In the 
ever-constraint budgetary context, vaccination budgets shall be preserved or even 
increased to sustain life-course approach of immunization at sufficient coverage 
rates.
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Objectives: To compare the total value of payer’s expenditures on Victrelis 
(boceprevir) and Incivo (telaprevir) in patients with chronic HCV GT1 estimated in 
the manufacturers’ Budget Impact Analyses (BIAs) submitted with the reimburse-
ment applications to AOTMiT and actual expenditures of the National Health Fund 
(NHF). MethOds: Annual public payer’s expenditures estimated in manufacturers’ 
BIAs for Victrelis and Incivo and actual expenditures reported by the NHF were com-
pared. RSSs were not taken into account. Analysed drugs were chosen on the basis 
of the same indication and financing through the same therapeutic programme 
in Poland. Actual expenditures and population size were taken from the finan-
cial reports of the NHF for the first and second year (actual data on 9 months for 
expenditures and 11 months for population size were extrapolated to one year) of 
reimbursement for each drug. Results: For drugs Victrelis and Incivo in patients 
with chronic HCV genotype 1 infections, the sum of total expenditures estimated 
in BIAs submitted with the reimbursement applications was 145,38 million PLN in 
the first year and 164,49 million PLN in the second year, and they were higher than 
the actual expenditures reported by the NHF: 77,48 million PLN and 120,72 million 
PLN, respectively. The expenditures estimated in BIAs were overestimated by 88% 
in the first year of reimbursement and 36% in the second year of reimbursement. 
Population size estimated in BIAs in comparison to its actual size from the NHF 
reports was overestimated by 53% in the first year and 38% in the second year 
of reimbursement. cOnclusiOns: In the case of drugs chosen for this analysis, 
total payer’s expenditures estimated in BIAs submitted with the reimbursement 
applications were overestimated in comparison to the real life expenditures of 
the NHF in Poland.
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Objectives: To assess the costs of vaccination throughout life for a fully immu-
nized Western European citizen. MethOds: Vaccines recommended in the most 
recent National Vaccination Calendar (NVC) for Germany, England, France, Italy, 
Spain, Sweden and Portugal were used differentiating men from women and healthy 
individuals from those suffering from underlying condition(s) who require specific 
additional vaccinations. Unit vaccine costs and administration fees were retrieved 
from national official sources. The number of visits was adjusted for possible co-
administrations to better reflect local vaccination practices. All costs were calculated 
from the national healthcare perspective. In sensitivity analyses, vaccine costs were 
varied within a +/-30% range to account for possible price variations due to competi-
tion, market type, size and vaccines lifecycle. Administration fees were increased 
by 30% hypothesizing that medical fees are unlikely to decline over time. Results: 
Vaccinating an individual against up to 19 diseases throughout his entire life and 
in full compliance with NVC would range from € 350 to € 2,400 (vaccines costs only) 
and from € 450 to € 3,400 when administration costs are considered. Lowest range 
corresponds to healthy man in Sweden and highest range to woman with underly-
ing conditions in England. Vaccination costs were variable among countries due 
to heterogeneous NVCs and vaccination organization. In all countries but France, 
adults (18-64y) and elderly (≥ 65) accounted for the lowest vaccines costs com-
pared to pediatric (0-24m) and children/adolescents (2-17y). In comparison, other 
mass secondary prevention may be at least 3 times more costly. cOnclusiOns: 
Vaccination requires a relatively low amount of money per individual knowing that 
some missed opportunities remain in senior vaccinations. A life-course approach 
of vaccination should be considered as a smart investment providing substantial 
benefit falling actually well beyond individual health and protecting the whole 
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mine the impact of parameter uncertainty. Results: With universal vaccination 
at a cost per dose of Php 624 for PCV10 and Php 700 for PCV13, both PCVs are cost-
effective compared to no vaccination given the ceiling threshold of Php 120,000 per 
QALY gained, yielding ICERs of Php 68,182 and Php 54,510 for PCV10 and PCV13, 
respectively. Partial vaccination of 25% of the birth cohort resulted in significantly 
higher ICER values (Php 112,640 for PCV10 and Php 84,654 for PCV13) due to loss 
of herd protection. The budget impact analysis reveals that universal vaccination 
would cost Php 3.87 billion to 4.34 billion per annual, or 1.6 to 1.8 times the budget 
of the current national vaccination program. cOnclusiOns: The inclusion of PCV 
in the national immunization program is recommended. PCV13 achieved better 
value for money compared to PCV10. However, the affordability and sustainability of 
PCV implementation over the long-term should be considered by decision makers.
PIN117
scorINg aND measuremeNt ProPertIes of a tool to assess PrImary 
care PHysIcIaNs’ eNgagemeNt IN aND PerceIveD BarrIers to 
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Objectives: Primary care physicians (PCPs) play a key role in France in the prescrip-
tion and administration of recommended vaccines. Uneven vaccination coverage in 
vulnerable populations appeals for specific interventions to be designed to address 
existing barriers faced by targeted groups of PCPs. The ‘Determinant of Intentions 
of VAccination’ (DIVA©) questionnaire was developed to assess PCPs’ attitudes and 
beliefs toward vaccination. The objectives of the study were to define the scoring rules 
and to assess the measurement properties of the DIVA questionnaire. MethOds: 
A cross-sectional study was conducted in France with PCPs to define the scoring 
of DIVA and to assess its measurement properties. PCPs had to complete the DIVA 
questionnaire in to any of the six vaccine-preventable diseases (VPD) they were ran-
domly assigned (measles, pertussis, pneumococcus infection, seasonal influenza, 
HVP infection and tetanus). Internal consistency reliability and known groups valid-
ity were assessed. Results: DIVA was completed by 1,069 PCPs (mean age 48; 58% 
male), with very good quality of completion (90% of questionnaires with no missing 
item). One redundant item was removed from the questionnaire. The final DIVA was 
composed of 55 items, grouped into six thematic domains covering disease, vaccine, 
information, organisation, consultation, and PCP experience, and one domain assess-
ing PCP’s engagement. The Engagement score showed very good internal consist-
ency reliability across the six VPD (0.80≤ Cronbach’s alpha< 0.90). The Rasch model 
validated the number, content and modalities of items of the Engagement domain. 
The six thematic scores showed overall good known groups validity. cOnclusiOns: 
DIVA is a valid and reliable measure to assess PCPs’ engagement toward vaccination, 
as well as the specific barriers they face in various VPD. DIVA might help to define 
specific interventions aimed at improving PCPs vaccination activity, and can serve as 
an outcome measure to assess the impact of such interventions.
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Objectives: Follow-up of critical laboratory results can present a challenge in 
resource limited settings due to high patient volumes, overstretched human 
resources and no systematic communication from the laboratory. An audit con-
ducted in 2013 in a large outpatient HIV-center revealed that < 50% of critical 
results were acted upon within 24 hours. Our objective is to describe the impact 
of the new developed guidelines on reducing mortality of patients with critical 
results. MethOds: Results must be immediately communicated by the labora-
tory to a physician via an “on-call phone”; patients should be contacted and asked 
to return to the clinic. In addition all critical laboratory results were reviewed 
and tagged by Quality Management staff. Design: retrospective survey of all files 
of patients who had in 2014 at least one of the following: Hb < 5.5g/dl, creati-
nine > 3.4mg/dl, positive serum Cryptococcus-Antigen (Crag). Clinician’s actions 
were categorized and described. Turnaround time was determined and incidence 
of mortality between 2013 and 2014 compared. Results: During 2014, 5,907 
patients had any laboratory test done. Hb < 5.5g/dl: 36(0.6%) patients. Action taken: 
blood transfusion 17/36 (47%), heamatinics14/36(39%) and 2/36(6%) dewormed. 
Creatinine > 3.4mg/dl: 64/3291(1.9%) patients. Action taken: antiretroviral treat-
ment regimen switched 43/64(67%), 2/64(3%) stopped, 12/64(19%) referral to the 
renal unit. Positive serum-Crag 17/464(3.7%). Action taken: 12/17(71%) started on 
fluconazole, 5/17(29%) were already on treatment. Turnaround time for Hb and 
serum crag was < 1 day, creatinine 13.3 days. From 2013 and 2014 the mortality 
decreased in patients with Hb< 5.5g/dl from 27.9 to 2.8%, with creatinine> 3.4mg/dl 
from 32.9 to 3.1% and with positive serum-Crag from 36.4 to 23.5%. cOnclusiOns: 
Critical results monitoring system greatly improves patient turnaround time, 
and reduces mortality through timely communication and patients follow up. 
We believe our system could serve as a role model for similar programs in Sub-
Saharan Africa to improve quality of care.
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in specialists compared to GPs (23,5% vs 14,0% respectively, P< 0,04, CI 1,05-3,38). On 
contrary, more specialists chose to never discuss antibiotic treatment with patients 
compared to GPs (19,1% vs 7,2%, P< 0,001, CI 1,46-6,2) and there were more GPs 
that always discussed antibiotic treatment with patients compared to specialists 
(15,8% vs 5,9%, P< 0,01, CI 0,14-0,78). Patients’ co-payment seems to be more sensi-
tive issue for GPs compared to specialists since 29% of GPs considered co-payment 
all the time or most of the time when choosing ATB compared to specialists (18,4%, 
P= NS). cOnclusiOns: This survey revealed that both GPs and specialists are 
aware of the importance of antimicrobial resistance and demonstrated differences 
between specialties with respect to antimicrobial use and knowledge. Antimicrobial 
education is needed but may be more effective if it is tailored to specific specialties.
PIN114
IDeNtIfyINg researcH gaPs IN aNtImIcroBIal resIstaNce (amr): 
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Objectives: Generate research questions through studies published and financed 
by government or public research intuitions is an important tool in management 
of the public health system. While there are a growing number of papers, guide-
lines and funding in research, there are specific needs for different countries that 
need answers. Thus, researching gaps within the needs of each country contrib-
utes to optimization of public spending and guidance for promoting effective 
research. MethOds: We conducted a search in the Brazilian database “Pesquisa 
Saúde” as in the international databases Pubmed Health; Cochrane Library and 
Prospero. For the international databases, we used the terms: “ Drug Resistance, 
Microbial”, “Antimicrobial Drug Resistances” and “Resistance, Antibiotic” with meta-
analyzes within 10 years cutouts. Results: A total of 212 trials were identified. 
Those trials were scored as 1 for the most important and 2 for least significant, 
according to local priorities. We obtained 107 studies with a score 1. These studies 
were carefully analyzed to guide which unanswered questions should develop in 
new researches. cOnclusiOns: Clinical and epidemiological characterization of 
gaps has been identified on mortality and morbidity, related with antimicrobial 
prescribing patterns. We also identified gaps in prevention and control of prescrip-
tion practices, colonization time in patients and detection of Mycobacterium tuber-
culosis strains. About economic impact and cost of RAM for the health system we 
identified gaps in hospital infections. The gaps identified will subside the financing 
of new studies by DECIT / MS in order to contribute to the national plan for preven-
tion and combating RAM which is part of the WHO global plan.
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Objectives: This article describes the epidemiological features of spread of HIV 
infection in the Republic of Kazakhstan. We have examined gender-specific of HIV- 
infection in the Republic of Kazakhstan. As of December 31, 2013, 19 905 cases of 
HIV- infection have been registered in the country, 1933 persons of which were 
tested positive for AIDS, 1431 persons died. MethOds: All the cases of HIV- trans-
mission in Kazakhstan for 26 years (1987-2013) have been analyzed. Statistical data 
was processed by means of BIOSTAT program. Extensive, crude, age indexes were 
calculated based on the general methods of health statistics Results: The preva-
lence of HIV in Kazakhstan is 86,5 out of 100 thousand people (0,090/0000), while 
the age group is people from 15 years old and older- 0,140/0000. Unequal distribu-
tion of the cases of HIV-infection on the territory of Kazakhstan is being observed. 
Accroding to the cumulative figures (1987 – 2013), 60,9% of HIV-positive people got 
an infection parentally (during the intravenous injection of narcotic substances), 
while the ratio of the persons with sexually transmitted infection is 34%. In 2013, the 
sexual transmition (heterosexual) of HIV-infection constitued 59,8%, while parental 
transmission made 33,5%. The highest ratio among the registered cases falls within 
the age group of 20 to 39 years old, i.e. 70,7%. Over the past years, the proportion of 
women in the disease detection structure is 44,1% (in 2011 - 39,6%; in 2012- 41,9%), 
the proportion of men among the detected cases is decreasing - 55,9% (in 2011 - 
60,4%; in 2012 - 58,1%). cOnclusiOns: Epidemiological analysis shows that the 
number of HIV-positive is increasing, the largest part of them are young people at 
the age of 20 to 39 years old. The ratio of HIV-positive women has increased, the 
infection transmission route has changed- the heterosexual transmission is taking 
the leading position.
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Objectives: The objective of this study is to assess the value for money of introduc-
ing pneumococcal conjugate vaccines as part of the immunization program in a 
lower-middle income country, the Philippines, which is not eligible for GAVI support 
and lower vaccine prices. It also includes the newest clinical evidence evaluating 
the efficacy of PCV10, which is lacking in other previous studies. MethOds: A 
cost-utility analysis was conducted. A Markov simulation model was constructed 
to examine the costs and consequences of PCV10 and PCV13 against the current 
scenario of no PCV vaccination for a lifetime horizon. A health system perspective 
was employed to explore different funding schemes, which include universal or 
partial vaccination coverage subsidized by the government. Results were presented 
as incremental cost-effectiveness ratios (ICERs) in Philippine peso (Php) per QALY 
gained (1 USD = 44.20 Php). Probabilistic sensitivity analysis was performed to deter-
